Drug Trial Radar · NCT05505916
An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)
Last checked: Nov 19, 2026Latest source record: Jun 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
145
Actual
Start
Oct 24, 2022
Primary completion
May 27, 2026
Study completion May 27, 2026
Sponsor
- Lead sponsor
- KalVista Pharmaceuticals, Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 18, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, multicenter extension trial to evaluate the long-term safety of KVD900 in patients who are 12 years or older with HAE type I or II.
Conditions
- Hereditary Angioedema
Interventions
KVD900 600 mgDrug
KVD900 Tablet 600 mg (2 x 300 mg)
KVD900 300 mgDrug
KVD900 Tablet 300 mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequencies and percentages of patients with AEs, AEs within 2 days of IMP administration, serious AE's and AEs causing premature discontinuation.Time frame: AEs will be recorded from the first dose of IMP in the KVD900-302 trial up to and including the end of study (EOS) visit, a maximum of 2 years for each patient.
- Number and percentage of patients with normal or abnormal laboratory results at each scheduled visit.Time frame: Throughout the duration of the trial.
- Number and percentage of patients with normal or abnormal vital sign results at each scheduled visitTime frame: Throughout the duration of the trial.
Locations
71 sites in 23 countries. Site status is shown where the registry gives one.
KalVista Investigative Site
Scottsdale, Arizona
KalVista Investigative Site
Little Rock, Arkansas
KalVista Investigative Site
San Diego, California
KalVista Investigative Site
San Diego, California
KalVista Investigative Site
Santa Monica, California
KalVista Investigative Site
Centennial, Colorado
KalVista Investigative Site
Colorado Springs, Colorado
KalVista Investigative Site
Evansville, Indiana
KalVista Investigative Site
Overland Park, Kansas
KalVista Investigative Site
Louisville, Kentucky
KalVista Investigative Site
Chevy Chase, Maryland
KalVista Investigative Site
Plymouth, Minnesota
KalVista Investigative Site
St Louis, Missouri
KalVista Investigative Site
Charlotte, North Carolina
KalVista Investigative Site
Cincinnati, Ohio
KalVista Investigative Site
Toledo, Ohio
KalVista Investigative Site
Hershey, Pennsylvania
KalVista Investigative Site
Dallas, Texas
KalVista Investgative Site
Layton, Utah
KalVista Investigative Site
Spokane, Washington
KalVista Investigative Site
Campbelltown, Australia
KalVista Investigative Site
Wein, Austria
KalVista Investigative Site
Sofia, Bulgaria
KalVista Investigative Site
Montreal, Canada
KalVista Investigative Site
Grenoble, France
KalVista Investigative Site
Lille, France
KalVista Investigative Site
Paris, France
KalVista Investigative Site
Berlin, Germany
KalVista Investigative Site
Frankfurt, Germany
KalVista Investigative Site
Mainz, Germany
KalVista Investigative Site
Mörfelden-Walldorf, Germany
KalVista Investigative Site
Athens, Greece
KalVista Investigative Site
Athens, Greece
KalVista Investigative Site
Budapest, Hungary
KalVista Investigative Site
Haifa, Israel
KalVista Investigative Site
Petach Tikvah, Israel
KalVista Investigative Site
Ramat Gan, Israel
KalVista Investigative Site
Tel Aviv, Israel
KalVista Investigative Site
Padova, Italy
KalVista Investigative Site
Palermo, Italy
Showing 40 of 71 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.